Vitiligo

A panel of experts discuss the diagnosis and pathophysiology of vitiligo.

The VIOLIN study examined the burden of disease, prevalence, and treatment of vitiligo in patients in France.

PRP is both safe and effective and may be used as a therapeutic option or alternative in conditions like vitiligo or in wound healing.

Both modalities achieved positive results and accurate ablation in cultured epithelial sheets transplantation for patients with vitiligo.

Scientists say the new findings could lead to new drugs for vitiligo and other pigmentation diseases.

The multi-million-dollar study will identify signatures of at-risk patients that may predispose them to developing vitiligo.

A pediatric patient with treatment-resistant vitiligo experienced improvements in depigmentation in as few as 9 treatments.

A systematic review found that combination therapy proved more efficacious in treating patients with vitiligo as opposed to the excimer laser alone.

Incyte representative Todd Edwards discusses how the awards help address challenges faced by patients with vitiligo.

As we have surpassed the halfway mark of 2023, Dermatology Times is spotlighting vitiligo coverage and news from the first half of year.

The authorization comes just over 2 months after the drug’s approval in the European Union.

Trained immunity may act as an enhancer and continuous trigger in the disease’s pathogenesis.

The combination of therapies achieved significant efficacy, with researchers noting a higher cure rate than is evident in other therapies for the condition.

In recognition of World Vitiligo Day, the Dermatology Times team is spotlighting advances and educational opportunities for the condition.

Despite this, researchers found that Hsp70 plasma levels did not correlate with the extent of disease.

Investigators compared data among patients with vitiligo and the general population.

More research is needed to specify long-term efficacy of the treatment and its ideal dose.

Pandya gives an in-depth overview of his vitiligo treatment pearls from the 2023 Pigmentary Disorders Exchange Symposium.

Hamzavi spoke at the 2023 Pigmentary Disorder Exchange Symposium in Chicago.

The pigment disorder is associated with several autoimmune and systemic comorbidities.

Researchers compared counts between patients with vitiligo and a control group of patients.

Researchers have identified what may be the first report of vitiligo induced de novo by dupilumab therapy.

Ruxolitinib is the first and only approved treatment for repigmentation in the European Union.

Despite a lack of FDA-approved treatments and management options for patients with vitiligo, both dermatologists and patients alike have options for care.

Researchers said laser and intense pulse light-induced vitiligo lacks consensus in prevention and safety measures.